<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572009</url>
  </required_header>
  <id_info>
    <org_study_id>RC20_0278</org_study_id>
    <nct_id>NCT04572009</nct_id>
  </id_info>
  <brief_title>Validation of a Biomathematical Model to Help Identify the Parameters of Flexible Insulin Therapy</brief_title>
  <acronym>ModIF</acronym>
  <official_title>Validation of a Biomathematical Model to Help Identify the Parameters of Flexible Insulin Therapy: Monocentric, Controlled, Randomized and Prospective Pilot Clinical Study in Patients With Type 1 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes is an autoimmune disease that requires daily treatment with insulin. The use&#xD;
      of subcutaneous pumps for continuous insulin delivery has been an important advance for&#xD;
      diabetic patients. The evolution of technologies through the miniaturization of insulin pumps&#xD;
      and the advent of continuous glucose sensors has made it possible to understand the&#xD;
      development of the artificial pancreas. Several teams are working on the development of an&#xD;
      artificial pancreas with considerable progress in closed-loop insulin delivery, particularly&#xD;
      during the night.&#xD;
&#xD;
      The Laboratory of Digital Sciences of Nantes has developed a new bio-mathematical model&#xD;
      describing the glucose-insulin dynamics, closer to the physiological reality of patients with&#xD;
      type 1 diabetes. This model allows firstly to identify the parameters of flexible insulin&#xD;
      therapy (basal rate, insulin sensitivity, carbohydrate ratios).&#xD;
&#xD;
      The objective of this study is to test the relevance of this bio-mathematical model to help&#xD;
      the physician identify the parameters of flexible insulin therapy (basal rate, insulin&#xD;
      sensitivity, carbohydrate ratios).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open randomized pilot clinical study, comparing the effectiveness of medical&#xD;
      decision assisted by this bio-mathematical model (&quot;augmented physician&quot;) versus unassisted&#xD;
      medical decision, to define the parameters of flexible insulin therapy based on data from a&#xD;
      continuous glucose measurement record for 7 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of time in glycemic target</measure>
    <time_frame>4 weeks</time_frame>
    <description>percentage of time in glycemic target (70-180 mg/dL) during the four weeks following medical consultation where the parameters of flexible insulin therapy are estimated by the physician, either conventionally or with the help of the bio-mathematical model, and parameterized in the insulin pump.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coefficient of variation of glucose</measure>
    <time_frame>75 days</time_frame>
    <description>Hypoglycemic readings &lt; 0.7 g/L, Time below 0.7 g/L, Time above 1.8 g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of severe hypoglycemia</measure>
    <time_frame>75 days</time_frame>
    <description>Frequency of severe hypoglycemia (requiring the intervention of a third party)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Robustness of the model</measure>
    <time_frame>75 days</time_frame>
    <description>for each glycemic holter, identification of the model from the first 3 days of recording and comparison during the last 3 days of the predicted results with the observed glucose levels. And comparison, in the &quot;delayed modelling&quot; arm, of the doses estimated by the diabetologist and the doses estimated from the model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of patient compliance</measure>
    <time_frame>75 days</time_frame>
    <description>evaluation of the difference between the theoretical doses recommended following modelling and the actual doses given by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of patient acceptance</measure>
    <time_frame>75 days</time_frame>
    <description>Quality of life questionnaire SF36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the average time of medical consultation in each group.</measure>
    <time_frame>75 days</time_frame>
    <description>Duration of the consultation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in heart rate over time</measure>
    <time_frame>75 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in activity over time</measure>
    <time_frame>75 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Augmented physician</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medical decision assisted by the bio-mathematical model to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Unassisted medical decision to define the parameters of flexible insulin therapy based on data from a continuous glucose measurement record.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bio-mathematical model</intervention_name>
    <description>bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)</description>
    <arm_group_label>Augmented physician</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Without bio-mathematical model</intervention_name>
    <description>No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with type 1 diabetes for at least two years with an indication for sensor&#xD;
             placement,&#xD;
&#xD;
          2. Patient patient with at least 6 months of external insulin pump therapy and using the&#xD;
             Medtronic 640G pump with or without the EnliteÂ® System.&#xD;
&#xD;
          3. Patient having at least 6 months experience of flexible insulin therapy,&#xD;
&#xD;
          4. Patient with HbA1c &lt;10% (less than 4 months' duration of testing in a medical&#xD;
             laboratory or equivalent),&#xD;
&#xD;
          5. Patient who has been wearing a Continuous Glucose Monitoring device for at least 3&#xD;
             months,&#xD;
&#xD;
          6. Adult patient,&#xD;
&#xD;
          7. Patient affiliated to a Social Security or equivalent,&#xD;
&#xD;
          8. Patient who has signed Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with type 2 diabetes or secondary diabetes&#xD;
&#xD;
          2. Patient with any serious medical condition that may affect participation in the study,&#xD;
&#xD;
          3. Patient benefiting from a legal protection measure,&#xD;
&#xD;
          4. Woman who is pregnant or likely to become pregnant during the course of the study,&#xD;
             i.e., a lack of effective contraception in women of childbearing age,&#xD;
&#xD;
          5. Breastfeeding,&#xD;
&#xD;
          6. Psychological and/or physical condition that may affect the proper monitoring of study&#xD;
             procedures,&#xD;
&#xD;
          7. Severe hypoglycemia leading to convulsions or loss of consciousness within the last 12&#xD;
             months,&#xD;
&#xD;
          8. Decreased hypoglycemic feelings (as judged by the clinician),&#xD;
&#xD;
          9. Impaired renal function (creatinine clearance calculated by CKD-EPI &lt; 30mL/min),&#xD;
&#xD;
         10. Patient who has had a pancreas transplant or pancreatic islets,&#xD;
&#xD;
         11. Persons with severe uncorrected hearing and/or visual acuity problems,&#xD;
&#xD;
         12. Insulin resistance defined by daily insulin requirements &gt; 1 U/kg/day in the week&#xD;
             prior to inclusion,&#xD;
&#xD;
         13. Patient treated with oral corticosteroid therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucy CHAILLOUS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucy CHAILLOUS, Dr</last_name>
    <phone>02.53.48.27.07</phone>
    <phone_ext>+33</phone_ext>
    <email>lucy.chaillous@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy CHAILLOUS, Dr</last_name>
      <phone>02.53.48.27.07</phone>
      <phone_ext>+33</phone_ext>
      <email>lucy.chaillous@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Lucy CHAILLOUS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 diabetes mellitus</keyword>
  <keyword>biomathematical model</keyword>
  <keyword>Flexible insulin therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

